Shares of the medical device maker Boston Scientific Corp. declined Tuesday, a day after the company said it had agreed to buy Rhythmia Medical Inc., a Burlington developer of medical software. Boston Scientific will pay about $90 million upfront and make as much as $175 million in milestone payments over five years. Rhythmia develops mapping and navigation software for use in cardiac catheter ablations, a way to treat abnormal heart rhythms, and other electrophysi0logy procedures, including atrial fibrillation and atrial flutter.
Boston Scientific Corp.’s shares slip
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week